GlassScriptPhysician profile
Asma Rashid
NPI 1639667421
$4,478.55
in general payments reported to CMS, 2019-2025
29 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $317 · 2024: $1,335 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,337.52 |
| Education | $141.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $635.06 | 2024-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $481.81 | 2023-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $461.38 | 2023-2025 | Filspari |
| Amgen INC. | $443.95 | 2024-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $439.55 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $221.18 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.12 | 2023-2025 | |
| Daiichi Sankyo INC. | $180.50 | 2023-2025 | Injectafer |
| Novo Nordisk INC | $174.99 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $154.29 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $147.71 | 2025 | Vafseo |
| Ardelyx, INC. | $145.82 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $124.99 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.91 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $89.27 | 2025 | Empaveli |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $88.90 | 2023-2025 | Purified Cortrophin Gel |
| Renalytix Ai, INC. | $64.93 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Veloxis Pharmaceuticals, INC. | $43.85 | 2024 | Envarsus |
| Opko Pharmaceuticals, LLC | $43.48 | 2023-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $40.63 | 2023-2024 | Ultomiris |
| Recordati_rare_diseases_inc. | $25.38 | 2025 | Cystadrops |
| Cormedix INC. | $25.10 | 2025 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.83 | 2024 | Jynarque |
| Chiesi USA, INC. | $22.32 | 2024 | Elfabrio |
| Cmp Pharma, INC. | $20.13 | 2024 | Tadliq, Liqrev, Atorvaliq |
| Nxstage Medical, INC. | $17.36 | 2024 | |
| Glaxosmithkline, LLC. | $16.67 | 2024 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $14.38 | 2023 | Lupkynis |
| Ascendis Pharma Endocrinology INC | $14.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.